S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: The truth about war with China (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: The truth about war with China (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: The truth about war with China (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: The truth about war with China (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead

SELLAS Life Sciences Group (SLS) News Today

$1.68
+0.11 (+7.01%)
(As of 05/26/2023 ET)
Compare
Today's Range
$1.59
$1.70
50-Day Range
$1.35
$6.15
52-Week Range
$1.17
$5.58
Volume
149,377 shs
Average Volume
190,846 shs
Market Capitalization
$47.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.



SLS Media Mentions By Week

SLS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SLS
News Sentiment

1.59

0.75

Average
Medical
News Sentiment

SLS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SLS Articles
This Week

2

1

SLS Articles
Average Week

SourceHeadline
finance.yahoo.com logoSELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
finance.yahoo.com - May 25 at 6:47 PM
finance.yahoo.com logoSELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia
finance.yahoo.com - May 16 at 9:19 AM
MarketBeat logoSolaris Resources (CVE:SLS) Trading Down 2.7%
americanbankingnews.com - May 14 at 6:54 AM
finanznachrichten.de logoSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
finanznachrichten.de - May 12 at 7:05 AM
msn.com logoUnusual Call Option Trade in SELLAS Life Sciences Group (SLS) Worth $37.03K
msn.com - May 11 at 7:28 PM
finance.yahoo.com logoSELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
finance.yahoo.com - May 11 at 6:19 PM
markets.businessinsider.com logoSELLAS Life Sciences Group (SLS) Receives a Buy from Maxim Group
markets.businessinsider.com - May 5 at 2:40 PM
finance.yahoo.com logoSELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study
finance.yahoo.com - May 4 at 8:36 AM
finance.yahoo.com logoSELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
finance.yahoo.com - April 26 at 6:35 PM
markets.businessinsider.com logoSELLAS Life Sciences Group (SLS) Gets a Buy from Maxim Group
markets.businessinsider.com - April 21 at 1:06 PM
MarketBeat logoSolaris Resources (CVE:SLS) Stock Rating Reaffirmed by National Bank Financial
americanbankingnews.com - April 21 at 6:14 AM
finance.yahoo.com logoSELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
finance.yahoo.com - April 18 at 8:47 AM
MarketBeat logoCantor Fitzgerald Comments on SELLAS Life Sciences Group, Inc.'s FY2023 Earnings (NASDAQ:SLS)
americanbankingnews.com - March 24 at 2:20 AM
markets.businessinsider.com logoMaxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)
markets.businessinsider.com - March 18 at 10:00 AM
finanznachrichten.de logoSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
finanznachrichten.de - March 17 at 7:35 AM
msn.com logoSELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-line
msn.com - March 16 at 6:29 PM
finance.yahoo.com logoSELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
finance.yahoo.com - March 16 at 6:29 PM
finance.yahoo.com logoSELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
finance.yahoo.com - March 7 at 9:39 AM
msn.com logoWhy Sellas Life Sciences Shares Are Nosediving
msn.com - February 24 at 4:46 PM
finance.yahoo.com logoSELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
finance.yahoo.com - February 24 at 4:46 PM
finance.yahoo.com logoSellas Life Sciences raises $20 million from public offering of stock, warrants
finance.yahoo.com - February 24 at 4:46 PM
finance.yahoo.com logoSellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offering
finance.yahoo.com - February 24 at 8:01 AM
finance.yahoo.com logoHere's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situation
finance.yahoo.com - February 5 at 8:46 AM
finance.yahoo.com logoSELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
finance.yahoo.com - January 19 at 9:10 AM
finance.yahoo.com logoSELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
finance.yahoo.com - January 5 at 9:09 AM
finance.yahoo.com logoSELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients
finance.yahoo.com - December 13 at 5:59 PM
finance.yahoo.com logoSELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
finance.yahoo.com - December 13 at 8:45 AM
msn.com logoLooking Into SELLAS Life Sciences Gr's Recent Short Interest
msn.com - December 8 at 4:11 PM
technews.tmcnet.com logoSELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
technews.tmcnet.com - December 8 at 9:00 AM
finance.yahoo.com logoSELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
finance.yahoo.com - December 8 at 9:00 AM
finance.yahoo.com logoSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
finance.yahoo.com - December 6 at 4:07 PM
finance.yahoo.com logoSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model
finance.yahoo.com - December 1 at 6:41 PM
finance.yahoo.com logoSELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
finance.yahoo.com - November 30 at 8:41 AM
finance.yahoo.com logoSELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)
finance.yahoo.com - November 16 at 6:15 AM
finance.yahoo.com logoSELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated
finance.yahoo.com - November 15 at 10:08 AM
finance.yahoo.com logoSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
finance.yahoo.com - November 14 at 12:59 PM
finance.yahoo.com logoSELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
finance.yahoo.com - November 14 at 7:59 AM
seekingalpha.com logoSellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial
seekingalpha.com - November 10 at 2:50 PM
finance.yahoo.com logoSELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer
finance.yahoo.com - November 10 at 2:50 PM
finance.yahoo.com logoSELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients
finance.yahoo.com - November 10 at 2:50 PM
benzinga.com logoSELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
benzinga.com - November 3 at 12:05 PM
finance.yahoo.com logoSELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 3 at 10:02 AM
finance.yahoo.com logoSELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
finance.yahoo.com - November 2 at 4:00 PM
finance.yahoo.com logoThinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences?
finance.yahoo.com - October 25 at 9:41 AM
finance.yahoo.com logoSELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
finance.yahoo.com - October 17 at 9:23 AM
finance.yahoo.com logoSELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
finance.yahoo.com - October 11 at 8:36 AM
finance.yahoo.com logoSELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations
finance.yahoo.com - September 29 at 9:48 AM
finance.yahoo.com logoSELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
finance.yahoo.com - September 22 at 8:44 AM
finance.yahoo.com logoSELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th
finance.yahoo.com - September 14 at 9:14 AM
finance.yahoo.com logoSELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022
finance.yahoo.com - September 8 at 8:08 AM
Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:SLS) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -